UBS raised the firm’s price target on Carter’s (CRI) to $33 from $26 and keeps a Neutral rating on the shares. Carter’s reported better than expected Q3 results, but the report likely isn’t a positive for the stock, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRI:
- Carter’s Announces $500M Senior Notes Offering
- Carter’s price target raised to $25 from $22 at Wells Fargo
- Carter’s price target raised to $34 from $28 at Citi
- Carter’s price target raised to $26 from $23 at Barclays
- Carter’s Inc. Faces Risks and Challenges in Restructuring Efforts: Potential Impacts on Profitability